The International Waldenstrom’s Macroglobulinemia Foundation ((IWMF) is a patient-founded and patient-led international nonprofit organization with a simple but compelling vision and mission.
OUR VISION: A world without WM (Waldenstrom’s macroglobulinemia)
OUR MISSION: Support and educate everyone affected by Waldenstrom’s macroglobulinemia (WM) while advancing the search for a cure
The IWMF is committed to creating a world without WM by finding a cure. Since 1999, the IWMF has invested over $18 million in WM research projects throughout the world. Thanks to this research WM patients have better treatment options that can lead to deeper, longer lasting remissions, and fewer side effects.
September 10, 2015
Article
Emil Parente is a WMer with a real past, and he is happy to share it with others, particularly those who are newly diagnosed.
September 04, 2015
Article
Marguerite Regan tells her Waldenström's macroglobulinemia story.
January 30, 2015
Article
Ibrutinib becomes the first drug specifically approved for Waldenström's macroglobulinemia (WM), two months ahead of expectations.
FDA Approves Lorbrena as First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer
Imbruvica Plus Novel Agent May Improve Progression-Free Survival in Chronic Lymphocytic Leukemia
How Caregivers Can Become an Active Part of the Cancer Care Team
Strict Cleaning Protocols Induce Limited Traces of Virus That Causes COVID-19 in Cancer Centers